Why the study?
Do phosphodiesterase-5 (PDE5) inhibitors improve hemodynamics and lung function in patients with chronic heart failure?
Do phosphodiesterase-5 (PDE5) inhibitors improve hemodynamics and lung function in patients with chronic heart failure?
PDE5 inhibitors represent a potential adjunctive therapy for chronic heart failure by improving pulmonary hemodynamics and alveolar-capillary gas conductance.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PDE5 inhibitors in CHF with secondary PH; prospective RCTs required before any practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Marco Guazzi (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: